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Introduction
Transitional cell carcinoma (TCC) is the most prevalent 
neoplasm of the urinary bladder in dogs and cats.1,2 The 
most common tumour location in dogs is at the trigone.3 
However, in the largest study of feline bladder TCC 
to date, 55% of 20 tumours occurred at sites distant to 
the trigone.4
Several risk factors have been identified in dogs, 
including female gender, breed (Scottish Terrier, Shetland 
Sheepdog, Fox Terrier, Beagle, West Highland White ter-
rier and Airedale Terriers), obesity, exposure to topical 
and environmental insecticides, local industrial activity 
and possibly cyclophosphamide treatment.5–9 However, 
risk factors are largely unknown in cats, although older 
cats and male cats appear to be predisposed.4,10,11
In canine studies, treatment may involve surgery 
and/or medical management. Treatment by surgery 
alone, using partial cystectomy, resulted in median 
survival times (MST) of 8612 and 106 days.13 However, 
owing to the trigonal location of TCC in dogs and the 
difficulty in achieving complete surgical margins, 
several studies have focussed on medical manage-
ment. Chemotherapy regimes used in dogs with TCC 
have included an anthracyclin with a platinum drug; 
doxorubicin with cyclophosphamide; intravesicular 
thiotepa; carboplatin with piroxicam; cisplatin; mitox-
antrone with piroxicam, gemcitabine with piroxicam; 
and vinblastine; with MST of 358, 259, 57, 161, <180, 
350, 230 and 147 days, respectively.12,14–19 Therapy 
with the non-steroid anti-inflammatory drug (NSAID) 
piroxicam given alone resulted in an MST of 181 days 
in 34 dogs, with six complete/partial remissions and 
18 dogs with stable disease.20 Therapy with another 
NSAID, deracoxib, given alone resulted in an MST of 
323 days in 26 dogs, with four partial remissions and 
17 dogs with stable disease.21
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There are few studies on the treatment of TCC of the 
urinary bladder in cats, with only 48 confirmed cases 
reported in the literature, of which only 31 have accom-
panying clinical information.4,10,11,22–32 While it is there-
fore difficult to draw meaningful conclusions as to the 
efficacy of different treatment options, the MST in the 
largest of these studies (n = 20 cats) was 261 days.4 The 
majority of cats that were not treated were euthanased at 
the time of diagnosis.4,11,24,31 However, one cat was eutha-
nased after 10 days,32 two cats survived 3 weeks10,27 and 
another survived for 276 days4 without specific treat-
ment. Cats treated with surgery alone (n = 5) have sur-
vived for between 2 days and 6 months.4,10,11 Eight of the 
cats in the study by Wilson et al were treated with sur-
gery alone or with adjunctive therapy; in these cats the 
progression-free interval was 89 days.4 Owing to the 
demonstrated efficacy of piroxicam in dogs, NSAIDs 
have also been investigated for the treatment of TCC in a 
small number of cats. Wilson et al demonstrated survival 
times of 1, 23 and 208 days with the use of piroxicam 
alone in three cats.4
The exact anti-tumour action of piroxicam is 
unknown.33 One proposed mechanism is the inhibition 
of cyclo-oxygenase 2 (COX-2), as this isoenzyme is over-
expressed in various neoplasms, including bladder TCC, 
as seen in all 21 dogs in one study.34 However, Beam et al 
demonstrated COX-2 expression in only 37% of feline 
TCCs,35 suggesting that COX-2 inhibitors may have less 
potential as anti-tumour agents in cats compared to 
dogs. Meloxicam, rather than piroxicam, was chosen in 
the current study for a number of reasons: it is believed 
to have more selective inhibition of COX-2 over COX-1 
and so may have potentially less gastrointestinal and 
renal side effects; it has been shown to inhibit prolifera-
tion in cell lines (albeit canine) in a dose-dependent man-
ner similar to piroxicam;33 the authors had experienced 
significant side effects when using piroxicam in cats in 
their clinic but had, anecdotally, heard of good responses 
with meloxicam treatment of feline TCC in other clinics. 
Meloxicam is relatively safe for the long-term treatment 
of cats,36 even elderly cats with concomitant diseases 
(such as osteoarthritis and stable chronic kidney dis-
ease);37 it is licensed for long-term use in cats in the UK, 
albeit for the treatment of osteoarthritis.
Therefore, the aim of this study was to evaluate 
the clinical features and outcome of cats with TCC of 
the urinary bladder that were treated with meloxicam. 
Additionally, COX expression in TCC samples was eval-
uated and related to the clinical response to treatment.
Materials and methods
Clinical information
Clinical records were reviewed for all cats that presented 
with a urinary bladder mass to the Royal (Dick) School 
of Veterinary Studies (RDSVS), University of Edinburgh, 
between January 2001 and February 2008. Additional 
cases were collected during the same time frame from 
UK veterinary practitioners who contacted the RDSVS 
for advice. Inclusion criteria included the presence of a 
bladder mass identified on radiographic and/or ultra-
sonographic diagnostic imaging or direct visualisation 
at surgery, a diagnosis of TCC based on histopathology 
or cytology, a history of medical management with 
meloxicam (Metacam; Boehringer Ingelheim) and follow-
up information being obtainable.
Data collected included age at diagnosis, breed, gen-
der, duration of urinary tract-related clinical signs prior 
to the diagnosis of TCC and previous diagnoses if 
known, clinical signs at presentation, method of diagno-
sis, location of mass within the urinary bladder and size 
of the mass, whether metastases were detected, duration 
and dose of meloxicam therapy, history of concurrent 
surgical treatment, response to treatment, presence of 
concurrent urinary tract infection or evidence of renal 
failure, duration of survival and cause of death. The 
symptom-free interval (SFI) was defined as the time 
from initiation of treatment to the first episode of uri-
nary-tract related signs. This and the MST were calcu-
lated using the Kaplan-Meier product limit method. 
Information for follow-up was determined by examina-
tion of the case records or by email communication with 
the referring veterinarians.
COX immunohistochemistry
Archived formalin-fixed, paraffin wax-embedded tissue 
blocks, where available, were retrieved from the pathol-
ogists who made the original definitive diagnosis. The 
original histopathological diagnosis was re-confirmed 
by one of the authors (TJS). Any drug treatment (includ-
ing NSAIDs and glucocorticoids) administered prior to 
biopsy was ascertained from medical records.
Positive control samples comprised formalin-fixed, 
paraffin wax-embedded normal feline bladder mucosa 
and feline fetal kidney stained with antibodies to COX-1 
and COX-2, respectively. The choice of control tissues 
was based on previous studies.34,38–41 Additionally, blad-
der tissue from five cats that had been euthanased as a 
result of non-urological disease had COX-2 immunohis-
tochemistry performed.
Immunolabelling and scoring were performed using 
the technique of Hayes et al41 and briefly comprised 
microwaving antigen retrieval at pH 6, followed by auto-
mated labelling (Techmate Horizon; LJL Biosystems), 
using a standard, two-layer indirect method (EnVision; 
DakoCytomation). Chromogen staining was developed 
with diaminobenzidine and slides were counterstained 
with haematoxylin. Polyclonal rabbit anti-ovine COX-1 
antibody (Cayman Chemical) at a 1 in 400 dilution, plus a 
negative control comprising normal rabbit immunoglobu-
lin fraction (DakoCytomation), diluted 1 in 8000 was used 
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for the COX-1 arm. For COX-2 immunolabelling, the pri-
mary antibody (Polyclonal Anti-PGHS-2 Human 
C-terminus) was diluted 1 in 800. A specific pre-immune 
serum (Oxford Biomedical Research), diluted 1 in 800, 
was used for negative control purposes. A further nega-
tive control was performed for all samples in both the 
COX-1 and COX-2 arms, using antibody diluent alone 
instead of an immunoreactive fraction. Immunolabelling 
was described as focal (a single area), multifocal, patchy 
(numerous groups, fairly evenly distributed) or diffuse. 
A semi-quantitative estimation of the number of immuno-
labelled neoplastic cells was made and recorded as <1%, 
2–10%, 11–50%, 51–75% and 75–100%. Intensity of label-
ling was categorised as weak (+), moderate (++) or marked 
(+++); relative to the positive control tissue which was cat-
egorised as moderate (++). The intensity of labelling in the 
nucleus and cytoplasm was recorded separately.
Results
The medical records of 17 cats were examined. Three 
were excluded owing to lack of definitive diagnosis of 
TCC, one had insufficient clinical history and two cases 
were not included because they were not treated with 
meloxicam. Details of the 11 cats included in the study 
are given on Table 1 (eight domestic shorthair cats, one 
Siamese, one Chinchilla Persian and one Abyssinian cat). 
All cats were neutered; there were seven (64%) male and 
four (36%) female cats. The median age at diagnosis was 
14 years (range 9–18 years; mean 13.1 years).
The clinical signs exhibited prior to diagnosis included 
haematuria (10/11; 91%), stranguria/dysuria (8/11; 
73%) and acute urethral obstruction (1/11; 9%). One cat 
had no urinary tract-associated clinical signs; the blad-
der mass was detected during abdominal ultrasonogra-
phy performed to investigate vomiting. The median 
Table 1 Details of the 11 cats included in the study
Patient Age at 
diagnosis 
(years)
Gender Breed Duration 
of 
clinical 
signs 
related 
to the 
urinary 
tract 
(days)
Presenting 
signs
Mean 
meloxicam 
dose 
(mg/kg) 
PO q24h
Surgical 
treatment
Symptom-
free interval 
(days)
COX-2 
immunostaining
Survival 
(days)
1 10 MN Siamese 425 Haematuria, 
dysuria
0.2 NP 116 Positive 120
2 12 MN DSH 365 Haematuria 0.03 Partial 
cystectomy
183 Positive 246
3 14 FN DSH 154 Haematuria, 
dysuria
0.05 Partial 
cystectomy
243 Negative 375
4 16 FN DSH 2008 Haematuria, 
dysuria
0.05 NP Haematuria 
0; 
dysuria 121
Positive 123
5 15 MN DSH 14 Haematuria, 
dysuria
0.1 NP Haematuria 
28; 
dysuria 35
Positive 35
6 9 FN Persian 92 Haematuria, 
dysuria
0.02 NP 630 Positive Still alive 
at 2065
7 18 MN DSH 0 None 0.02 Partial 
cystectomy
321 Negative Still alive 
at 321**
8 16 MN Abyssinian 7 Haematuria, 
dysuria
0.01 NP 425 NP 493
9 10 MN DSH 7 Acute 
urethral 
obstruction; 
haematuria, 
dysuria
0.05 for 10 
days
Pre-pubic 
urethrostomy 
and partial 
cystectomy
0 NP 76*
10 15 FN DSH 7 Haematuria 0.03 NP 365 NP 1064
11 10 MN DSH 31 Haematuria, 
dysuria
0.02 Partial 
cystectomy
7 NP 10
FN = female neuter; MN = male neuter; DSH = domestic shorthair; NP = not performed
*Censored at 10 days when the treatment was changed to piroxicam
**No recurrence of bladder signs, but died of congestive heart failure at 390 days
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duration of urinary-related clinical signs prior to diag-
nosis was 61.5 days (range 1–2008; mean 310 days). 
Three cats had a previous diagnosis of feline idiopathic 
cystitis (FIC), based on urinalysis and diagnostic imag-
ing, with intermittent clinical signs from 365, 425 and 
2008 days prior to the diagnosis of TCC.
Abdominal contrast radiography and/or ultrasonog-
raphy were performed in 10 of the cats to determine 
bladder mass size, and extent and location of the 
mass(es). The remaining cat had TCC characterised 
by direct visualisation at exploratory celiotomy. 
Radiography was performed in eight (73%) cats and 
ultrasonography in seven (64%) cats. Five (46%) cats had 
both imaging modalities performed. Tumour location 
varied widely between cats, being craniodorsal 4/11 
(36%), cranioventral 4/11 (36%), affecting multiple sites 
1/11 (9%), causing diffuse thickening of the entire wall 
1/11 (9%) and affecting only the trigone area 1/11 (9%). 
The trigone was only affected in three (27%) cats.
The diagnosis of TCC was confirmed by histopa-
thology in nine (82%) cats and by cytology of suction 
catheter biopsies in two (18%) cats. Two cats had neo-
plastic transitional cells recorded on urine sediment 
examination. One cat had a prior fine needle aspiration 
biopsy, which was consistent with the histopathological 
diagnosis.
Staging for the presence of metastases was performed 
at the time of diagnosis in six cats. Three cats had both 
thoracic radiography and abdominal ultrasonography, 
two cats had only abdominal ultrasonography and one 
cat had only thoracic radiography. No metastases were 
detected in any cats at the time of diagnosis.
All cats were treated by oral administration of meloxi-
cam. A mean initial dose of 0.09 mg/kg (range 0.01–0.3) 
was given q24h for the first 3–7 days and a mean mainte-
nance dose of 0.04 mg/kg (range 0.01–0.1) was given 
thereafter. For 10 (91%) cats, meloxicam was the primary 
medical therapy used for treatment of TCC. The cat 
with acute urethral obstruction was given meloxicam 
0.05 mg/kg q24h for the first 10 days of treatment then 
changed to piroxicam (Feldene, Pfizer) 0.3 mg/kg orally 
q48h for the following 66 days until euthanasia. This 
was instituted because of the severity of disease and the 
previously demonstrated efficacy of piroxicam for the 
treatment of TCC in dogs.20 That cat also had a cytos-
tomy tube placed followed by pre-pubic urethrostomy 
to relieve urinary obstruction. Partial cystectomy was 
performed in four cats; surgical margins were reported 
as complete for one cat and incomplete in the other 
three cats.
Ten of the 11 cats showed clinical improvement. Only 
the cat with acute urethral obstruction continued to 
show haematuria and dysuria, although its demeanour 
did improve. The median SFI was 243 days (range 0–630) 
for haematuria and 334 days (range 0–630) for dysuria. 
Possible gastrointestinal side effects were seen as diar-
rhoea in the cat treated with piroxicam (which resolved 
in 24 h after missing one treatment dose) and an episode 
of melaena in a meloxicam-treated cat. One cat devel-
oped renal failure after 1 week of treatment with 
meloxicam and another cat developed renal failure after 
6 months of treatment. The first cat had a trigonal tumour 
and hydronephrosis, so the azotaemia was likely to have 
been obstructive in origin. Two cats had chronic renal 
disease at the time of diagnosis, which did not deterio-
rate appreciably on therapy.
The MST for all 11 cats was 311 days (range 10–1064) 
and a 1-year survival of 50% (Figure 1). The MST for 
those cats treated by partial cystectomy and meloxicam 
375 days was not statistically different from those 
treated with meloxicam alone (123 days; P = 0.87).
Death in eight out of the nine cats that died or were 
euthanased was related to the TCC; the remaining 
patient was euthanased owing to worsening arthritic 
pain and reduced mobility (cat 7). For those cats where 
death was a result of complications of TCC, five were 
euthanased because of recurrence of lower urinary 
tract-related clinical signs; two were euthanased owing 
to surgical complications [one because of pre-pubic ure-
throstomy stoma necrosis (cat 9) and the other as a result 
of uroperitoneum following partial cystectomy (cat 11)]; 
one died spontaneously following dyspnoea caused by 
pulmonary metastases and neoplastic pleural effusion 
(cat 10).
Post-mortem examination was performed in four 
(44%) of the cats that were euthanased or died. Three 
cats had TCC metastases at the time of death: in the 
lungs, kidney and local lymph nodes in one cat, in the 
lungs and pleura of another and in the peritoneum of 
the third cat.
Figure 1 Kaplan-Meier survival curve for the nine cats that 
died during this study. Mean survival time was 264 days.  
The short vertical lines represent censored cases: cats 6 and 
7 as they were still alive at the time of writing, and cat 9 that 
was censored at 10 days as treatment was changed from 
meloxicam to piroxicam at that point
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COX immunohistochemistry was performed on TCC 
tissue samples from seven (64%) cats (Table 2). The TCC 
of all seven cats were COX-1 positive. Five of the TCCs 
(71%) were COX-2 positive and two (29%) were COX-2 
negative. All of the normal bladder tissue samples from 
the five control cats were COX-2 negative. Treatments 
administered within 1 month of biopsy sampling for 
histopathology included meloxicam (n = 2), meloxicam 
and marbofloxacin (Marbocyl; Vétoquinol) (n = 1) 
and no medication (n = 2) for the COX-2-positive cats. 
One of the COX-2-negative cats received meloxicam 
and amlodipine (Istin; Pfizer) and the other received 
pentosan polysulphate sodium (Cartrophen Vet; 
Arthropharm) and fluoxetine hydrochloride (Prozac; 
Eli Lilly). The MST for cats with COX-2-positive 
TCC was 123 days and 375 days for cats with COX-2-
negative TCC.
Discussion
This study is the first to demonstrate the clinical features 
and response to meloxicam therapy (plus or minus sur-
gery) of a group of feline patients with bladder TCC. As 
this is a relatively rare neoplasm with a paucity of infor-
mation in the veterinary literature, this study serves 
to augment the body of knowledge on feline TCC in gen-
eral. Our findings agree with other studies in a number 
of areas. Our study confirms that feline TCC is a disease 
of geriatric cats, with no breed predisposition and a male 
bias.4 Also, unlike dogs and humans, our findings 
suggest that the majority of feline cases do not involve 
the bladder trigone.4,10 Haematuria is the most common 
clinical sign, with urination abnormalities, such as dysu-
ria, stranguria and pollakiuria, also being prevalent,4,10 
as our results demonstrate.
In previous studies, the median duration of clinical 
signs prior to diagnosis was 28 days,11,25,29–32 compared 
with 2 months in our case series. Three cats in the current 
study had a prior diagnosis of FIC, with clinical signs 
having been present over a prolonged period. While it is 
important not to over-interpret these findings when the 
numbers are so small, it could potentially be speculated 
that these were cases of TCC with a very long time course 
that had been originally misdiagnosed. However, it would 
seem unlikely that a cat with TCC would survive between 
1 and 5.5 years. Alternatively, it could be postulated that 
the chronic inflammation from FIC predisposed the cats 
to the development of TCC. There is a well-documented 
link between chronic inflammation and the development 
of some cancers in both animals and humans.42
In the current study, cats with TCC that were treated 
with meloxicam therapy (with or without surgical extir-
pation) had a MST of 8 months (311 days). This compares 
to canine patients treated with piroxicam having a MST 
of 181 days,20 or those treated with deracoxib having a 
MST of 323 days.21 Survival times of our cats treated 
with meloxicam were similar to those achieved by 
Wilson et al (MST 261 days);4 however, their 20 cats were 
treated with chemotherapy, piroxicam, surgery or a com-
bination of these modalities, so it is difficult to compare 
treatment options as there was an insufficient number 
receiving each treatment to allow for direct comparison.
Our data suggest that meloxicam may have a role to 
play in the palliative management of TCC in the urinary 
bladder of the cat. Further studies will be required to 
improve our knowledge of this drug’s efficacy in feline 
TCC and to determine whether a combination of NSAIDs 
and cytotoxic agents could confer a survival advantage, 
as seen in dogs given piroxicam and mitoxantrone 
(reported median survival of 291 days).17
Meloxicam inhibits COX enzymes, preferentially 
inhibiting COX-2 over COX-1. As COX-2 is over-
expressed in many neoplasms, including canine TCC,34 
we were interested in investigating whether COX-2 was 
over-expressed in the TCCs in our cases and whether 
COX-2 expression was associated with a positive 
response to therapy with meloxicam. In order to docu-
ment over-expression, we first had to determine the level 
of COX-2 expression in normal feline bladder. None of 
the five normal bladder samples showed any COX-2 
expression. However, COX-2 was over-expressed in the 
majority of our TCC cases (2/7; 71%), which was notably 
higher than previously documented (37%).35 The level of 
expression was low (<1%), similar to that for feline oral 
Table 2 COX-1 and COX-2 staining of seven of the cases
Immunolabelling characteristics COX-1 COX-2
Total negative 0 2
Total positive 7 5
Percentage positive cells
 <1% 0 5
 2–10% 0 0
 11–50% 1 0
 51–75% 2 0
 >75% 4 0
Labelling intensity
 Nuclear  
 + 0 0
 ++ 2 0
 +++ 0 0
 Cytoplasmic
 + 0 0
 ++ 6 5*
 +++ 0 0
Distribution
 Focal 0 0
 Multifocal 0 2
 Patchy 1 0
 Diffuse 6 3
*Three cases ++, two cases + to ++
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squamous cell carcinoma using the same methodology.41 
In the month prior to the biopsies being collected, three 
of the cats found to be COX-2-positive and one of the 
cats found to be COX-2-negative had received meloxi-
cam. These numbers are too small to be able to say 
whether or not meloxicam affected COX-2 staining.
The survival time for the meloxicam-treated cats was 
longer in COX-2-negative cats compared with COX-2-
positive cats. Confirmation of this unexpected finding 
would require a larger study. If, however, this finding is 
supported by future studies, it might indicate that the 
potentially beneficial effects of this NSAID may not be 
mediated by COX-2-regulated mechanisms. Indeed, 
other anti-neoplastic mechanisms of NSAIDs have been 
proposed, including the induction of apoptosis, interfer-
ence with cell-cycle progression, stimulation of immune 
surveillance and reduction of carcinogen activation or 
anti-angiogenic effects.42,43
In conclusion, we present the details of 11 cats with 
TCC affecting the urinary bladder, their clinical pres-
entation and diagnostic findings, and their clinical out-
come following treatment with meloxicam (plus or 
minus bladder surgery). The cats had a MST of 311 days 
which suggests that meloxicam may have a role to play 
in the palliative management of TCC in the urinary blad-
der of the cat
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